Bristol PA, USA, 26 April 2017 – Abzena intends to invest $5 million at its Bristol PA facility in order to increase its chemistry research and manufacturing services business for the biopharmaceutical industry. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange.
Abzena is a growing international life sciences services and technology group enabling the development of better biopharmaceuticals from three locations – Bristol PA, San Diego CA, and Cambridge, UK.
The Company’s services are utilised by a global customer base, including 18 of the top 25 major biopharmaceutical companies over the past three years.
Abzena’s Bristol operation has been part of the Abzena Group since the acquisition of The Chemistry Research Solution LLC (“TCRS”) in December September 2015. TCRS was founded in 2009 and has a strong reputation as a specialist chemistry services provider, particularly in the antibody-drug conjugate field, where it utilises a broad toolbox of ADC linker and payload reagents and analytical capabilities.. Abzena Bristol’s customers in the antibody drug conjugate field can also access Abzena’s ThioBridge technology for creation of superior, next-generation products, as well as the Group’s biomanufacturing capabilities in San Diego. Abzena currently employs 43 people in Bristol, having expanded the business over the last year as part of the Abzena group.
Through the investment program, Abzena will be establishing manufacturing capabilities for antibody-drug conjugates to enable its partners to progress these novel anti-cancer biopharmaceuticals into clinical trials. This further investment builds on Abzena’s existing capabilities for chemistry research services and manufacturing.
John Manzello, President Abzena (US), said:
“We are seeing a growing demand in the market for our chemistry services, particularly from major biopharmaceutical companies and innovative emerging biotech in the antibody drug conjugate field.
The Bristol team is recognised for its chemistry excellence and this investment program will enable Abzena to continue the growth of its business since TCRS became part of the group in 2015.”
John Burt, Chief Executive Officer
John Manzello, President Abzena (US)
Sven Lee, Chief Business Officer (US)
|+1 215 788 3603|
Melanie Toyne Sewell / Alex Shaw
|+44 20 7457 2020|
For recruitment enquiries, please contact Lee Wishnov at CareersUSBristol@abzena.com or for more information, please check Abzena’s website at www.abzena.com
Notes to Editors
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term ‘Abzena inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘Abzena inside’ products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
- Cell line development for the manufacture of recombinant proteins and antibodies;
- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com